Skip to content

US · CRMD · BIOTECHNOLOGY

CorMedix Inc. (CRMD) intrinsic value and stock valuation

$5.27as of 2026-11-21 · Mkt cap 583.68M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

CorMedix Inc. DCF and intrinsic value

InvestorsCraft values CRMD with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from CRMD’s statements →

CorMedix Inc. Graham Number

Graham Number: $16.93d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Biotechnology Parsippany, NJ 07054 cormedix.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$311.7M+319.5% 5y CAGRd
20112025
Net income
$163.1M
20112025
Free cash flow
$172.8M
20112025
Total equity
$405.3M+55.8% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$311.7M$43.5M$0.00$70K$190K
Operating income$150.1M-$-22.36M-$-48.96M-$-30.62M-$-29.44M
Net income$163.1M-$-17.93M-$-46.34M-$-29.7M-$-28.21M
EPSd$2.03M-$-304.57K-$-910.41K-$-737.52K-$-748.87K
Operating cash flow$175.1M-$-50.61M-$-38.41M-$-24.36M-$-21.16M
Capital expenditure-$-2.26M-$-120K-$-330K-$-220K-$-1.43M
Free cash flow$172.8M-$-50.73M-$-38.74M-$-24.58M-$-22.58M
Total assets$826.1M$118.9M$82.1M$62M$69M
Total debt$148.9M$520K$670K$800K$920K
Net debt$3.09M-$-40.13M-$-42.98M-$-42.57M-$-52.39M
Total equity$405.3M$84.7M$70.1M$55.1M$62.8M
Cash and short-term investments$149.5M$51.7M$76M$59M$65.5M
Income statement
20252024202320222021
Revenue$311.7M$43.5M$0.00$70K$190K
Cost of revenue$36M$3.19M$210K$0.00$150K
Gross profit$275.8M$40.3M-$-210K$60K$40K
Research and development expenses$19.3M$3.94M$13.2M$10.7M$13.1M
Selling, general and administrative expenses$30.2M$58.7M$35.8M$20M$16.4M
Other expenses$76.1M$0.00$0.00$0.00$0.00
Operating expenses$125.6M$62.6M$48.8M$30.7M$29.5M
Cost and expenses$161.6M$65.8M$49M$30.7M$29.6M
Interest income$3.85M$2.58M$2.68M$330K$10K
Interest expense$2.78M$40K$30K$30K$20K
Depreciation and amortization$15M$310K$70K$210K$180K
Ebitda$167.8M-$-18.98M-$-46.23M-$-30.05M-$-29.38M
Operating income$150.1M-$-22.36M-$-48.96M-$-30.62M-$-29.44M
Total other income/expenses, net-$-120K$3.03M$2.62M$340K-$-20K
Income before tax$150M-$-19.32M-$-46.34M-$-30.29M-$-29.46M
Income tax expense-$-13.04M-$-1.39M$0.00-$-590K-$-1.25M
Net income$163.1M-$-17.93M-$-46.34M-$-29.7M-$-28.21M
Weighted average shares outstanding$72M$58.9M$50.9M$40.1M$37.6M
Weighted average diluted shares outstanding$80.3M$58.9M$50.9M$40.3M$37.7M
Balance sheet
20252024202320222021
Cash and short-term investments$149.5M$51.7M$76M$59M$65.5M
Net receivables$171.2M$51.7M$0.00$0.00$50K
Inventory$29.7M$7.6M$2.11M$0.00$0.00
Total current assets$367.1M$114.6M$79.5M$59.6M$66.5M
Property, plant and equipment, net$9.93M$2.32M$2.51M$2.38M$2.37M
Goodwill and intangible assets$409.1M$1.84M$0.00$0.00$0.00
Long-term investments$10.4M$0.00$0.00$0.00$0.00
Total non-current assets$459.1M$4.27M$2.61M$2.49M$2.48M
Total assets$826.1M$118.9M$82.1M$62M$69M
Accounts payable$7.88M$1.72M$4.28M$2.2M$2.21M
Short-term debt$1.45M$170K$150K$130K$120K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$174.3M$33.8M$11.4M$6.31M$5.35M
Long-term debt$147.5M$350K$520K$670K$800K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$246.6M$350K$520K$670K$800K
Capital lease obligations$4.29M$520K$670K$800K$920K
Total liabilities$420.8M$34.2M$11.9M$6.98M$6.15M
Common stock$80K$60K$50K$40K$40K
Retained earnings-$-176.57M-$-339.63M-$-321.7M-$-275.36M-$-245.66M
Accumulated other comprehensive income (loss)$0.00$90K$90K$80K$90K
Total equity$405.3M$84.7M$70.1M$55.1M$62.8M
Total investments$14.1M$11M$32.4M$15.6M$12.2M
Total debt$148.9M$520K$670K$800K$920K
Net debt$3.09M-$-40.13M-$-42.98M-$-42.57M-$-52.39M
Cash flow statement
20252024202320222021
Net income$163.1M-$-17.93M-$-46.34M-$-29.7M-$-28.21M
Depreciation and amortization$14.6M$310K$70K$80K$60K
Stock-based compensation$13.8M$6.13M$5.49M$4.07M$5.04M
Change in working capital$7.33M-$-39.41M$2.23M$1.07M$1.84M
Accounts receivable-$-90.92M-$-51.79M$0.00$40K-$-40K
Inventory-$-3.48M-$-5.49M-$-2.11M$0.00$150K
Accounts payable$3.33M-$-2.56M$2.08M-$-10K$1.08M
Net cash provided by operating activities$175.1M-$-50.61M-$-38.41M-$-24.36M-$-21.16M
Investments in property, plant and equipment-$-2.26M-$-120K-$-330K-$-220K-$-1.43M
Acquisitions, net-$-308.51M$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-308.43M$21.2M-$-17.06M-$-3.71M-$-9.13M
Common stock issued$96.6M$18.9M$55.8M$17.8M$41.5M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$238.5M$26.3M$55.9M$17.9M$41.8M
Net change in cash$105.1M-$-3.07M$450K-$-10.18M$11.5M
Cash at end of period$145.8M$40.8M$43.8M$43.4M$53.6M
Operating cash flow$175.1M-$-50.61M-$-38.41M-$-24.36M-$-21.16M
Capital expenditure-$-2.26M-$-120K-$-330K-$-220K-$-1.43M
Free cash flow$172.8M-$-50.73M-$-38.74M-$-24.58M-$-22.58M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About CorMedix Inc.

        CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.

        CEO
        Joseph Todisco
        Employees
        191
        Beta
        1.48

        Explore

        Frequently asked questions

        What is the intrinsic value of CorMedix Inc. (CRMD)?

        InvestorsCraft does not currently publish an intrinsic value for CRMD. How the IC value is calculated.

        Is CRMD undervalued?

        InvestorsCraft does not publish an undervaluation signal for CRMD at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.